Open access – Page 26

Correction: Targeting CD93 on monocytes revitalizes antitumor immunity by enhancing the function and infiltration of CD8+ T cells

12 de November de 2024 by Journal for ImmunoTherapy of Cancer current issue

Correction: Inhibition of PNCK inflames tumor microenvironment and sensitizes head and neck squamous cell carcinoma to immune checkpoint inhibitors

9 de November de 2024 by Journal for ImmunoTherapy of Cancer current issue

CRLF2-rearranged B-cell ALL with extramedullary lineage switch to AML following CD19-targeted therapy

26 de October de 2024 by

Lineage switch (LS) refers to the immunophenotypic transformation of one leukemia lineage to another (ie, lymphoid to myeloid) with retention of baseline genetics. This phenomenon was originally observed in infants with B-lymphoblastic leukemia (B-ALL…

Correction: Phase I studies of davoceticept (ALPN-202), a PD-L1-dependent CD28 co-stimulator and dual PD-L1/CTLA-4 inhibitor, as monotherapy and in combination with pembrolizumab in advanced solid tumors (NEON-1 and NEON-2)

16 de October de 2024 by Journal for ImmunoTherapy of Cancer current issue

Targeted inhibition of the IL5 axis for immune checkpoint inhibitors eosinophilic-induced adverse events

12 de October de 2024 by Rubin, L., Talmon, A., Ribak, Y., Lavie, D., Nechushtan, H., Caplan, N., Lotem, M., Shamriz, O., Adini, I., Tal, Y.

Given the broad implementation of immune checkpoint inhibitors (ICI) for cancer therapy, we encounter a variety of immune-related adverse events (irAE) including immune-related blood eosinophilia. Eosinophilia demonstrated a potential positive predict…

Pretreatment CT-based machine learning radiomics model predicts response in unresectable hepatocellular carcinoma treated with lenvatinib plus PD-1 inhibitors and interventional therapy

26 de September de 2024 by Wu, X., You, J., Zhang, S., Zhang, B.

Case report of fatal immune-mediated myocarditis following treatment with davoceticept (ALPN-202), a PD-L1-dependent CD28 costimulator and dual PD-L1/CTLA-4 checkpoint inhibitor, in combination with pembrolizumab

14 de August de 2024 by

Engagement of programmed death-1 (PD-1) and cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) can interfere with the CD28 signaling requisite for T-cell activation. While immune checkpoint inhibitors (ICIs) can relieve this suppression, they are un…

Correction: ASCC3 promotes the immunosuppression and progression of non-small cell lung cancer by impairing the type I interferon response via CAND1-mediated ubiquitination inhibition of STAT3

10 de July de 2024 by Journal for ImmunoTherapy of Cancer current issue

Correction: Targeting SNORA38B attenuates tumorigenesis and sensitizes immune checkpoint blockade in non-small cell lung cancer by remodeling the tumor microenvironment via regulation of GAB2/AKT/mTOR signaling pathway

13 de May de 2024 by Journal for ImmunoTherapy of Cancer current issue

Response to: Correspondence on ‘Cardiovascular toxicities associated with bispecific T-cell engager therapy’ by Noguchi et al

22 de April de 2024 by Sayed, A., Munir, M., Poliner, M., Sughra, S., Epperla, N., Addison, D.

301 Moved Permanently